Independent intelligence for the laboratory world

Amprion Study Supports Skin-Biopsy Alpha-Synuclein Assay

Peer-reviewed research supports a skin-biopsy seed-amplification assay for distinguishing multiple system atrophy from related synucleinopathies.

Press release summary

Amprion highlighted peer-reviewed research showing that a skin-based alpha-synuclein seed-amplification assay can distinguish multiple system atrophy from neuronal synuclein diseases, including Parkinsonโ€™s disease and dementia with Lewy bodies. The study was published in npj Parkinsonโ€™s Disease.

The researchers reported agreement between skin and cerebrospinal-fluid testing, including concordance among samples from patients with prodromal Parkinsonโ€™s disease and dementia with Lewy bodies. Skin-assay positivity also increased as Parkinsonโ€™s disease progressed. Amprionโ€™s currently available SAAmplify-ฮฑSYN Plus laboratory-developed test uses cerebrospinal fluid; the skin assay remains a research-use method that the company plans to advance toward clinical commercialization.

Why it matters for laboratories

A validated skin-biopsy method could provide a more accessible specimen pathway than lumbar puncture for detecting misfolded alpha-synuclein and differentiating related neurodegenerative disorders. It may also expand biomarker options for clinical trials and patient stratification. The research is an important feasibility step, but laboratories still need standardized collection procedures, multicenter reproducibility data, defined clinical cutoffs and regulatory validation before routine diagnostic adoption.

Original source: Amprionโ€™s Oct. 5, 2026, announcement. The underlying study is available from npj Parkinsonโ€™s Disease.

Join the Discussion

Share your experience or ask a question about this article. Please keep comments relevant and respectful.

Leave a Reply

Your email address will not be published. Required fields are marked *